FDA Pushes Abortion Pill Safety Review to 2027, Drawing Criticism

A federal agency has extended the timeline for its ongoing safety assessment of the United States’ primary medication abortion drug, confirming that the review process will stretch into next year. This development drew immediate sharp criticism from anti-abortion advocates who had anticipated stricter regulations on the pill’s availability.

Timeline and Agency Findings

In a legal filing submitted late Wednesday, the Food and Drug Administration provided a court-ordered update on the progress of the reevaluation initiated by Health Secretary Robert F. Kennedy Jr. The agency stated it expects to finish a specific safety study by mid-December of this year. A comprehensive report detailing the findings is scheduled for release no later than March 2027. Following this report, the FDA will determine whether to impose new restrictions or implement other changes regarding the drug’s use.

The FDA noted in the filing that it employs a “statistical data mining method” to identify potential “unknown safety concerns.” This analysis relies on an electronic database aggregating reports of medical injuries and drug side effects from major health networks and insurers. Beyond the safety study, the agency indicated it is reviewing multiple petitions proposing modifications to how mifepristone is prescribed and distributed.

Political and Legal Context

Mifepristone received initial FDA approval in 2000. Over the subsequent years, the agency repeatedly reaffirmed the medication’s safety and effectiveness while easing several restrictions, including the elimination of the requirement for in-person dispensing. However, since President Donald Trump returned to the White House, anti-abortion groups and congressional allies have pressured the administration to revisit the pill with the goal of limiting its access.

Gavin Oxley, representing Americans United for Life, an anti-abortion organization, denounced the extension as a failure of “true leadership” by Trump administration officials. “The administration continues to find itself on the wrong side of women’s health, clearly uninterested in mitigating the ongoing harms caused by the abortion pill,” Oxley said.

The two-drug regimen involving mifepristone and misoprostol remains the most common form of abortion procedure in the U.S. Opponents have primarily targeted a 2021 decision permitting doctors to prescribe the drug online and mail it during the COVID-19 pandemic. That policy was made permanent under President Joe Biden in 2023, effectively undermining various state-level abortion bans by allowing remote access.

Judicial Proceedings and Standing

The FDA’s latest update was directed by a federal judge in a lawsuit filed by the state of Louisiana. The state alleges that mail-delivery of mifepristone compromises its abortion ban. This case is one of several state lawsuits concerning mifepristone currently navigating the judicial system.

Last month, a three-judge panel for the 5th U.S. Circuit Court of Appeals questioned the merits of Louisiana’s claim, specifically examining whether the state possessed legal standing to challenge the FDA’s oversight of the drug. Any ruling from the 5th Circuit would not immediately alter the regulatory landscape, as the Supreme Court has blocked changes to the drug until it reviews the case again.